Friedman, G., Goldschmidt, N., Friedlander, Y., Ben-Yehuda, A., Selhub, J., Babaey, S., Mendel, M., Kidron, M., & Bar-On, H
Based on the PIONEER programme, oral semaglutide has been licensed for people with T2D and the 14 mg dose, leads to HbA1c improvement up to 1.4% and WL up to 4.4 kg [20]
Frequency: Once per day (subcutaneous) during loading phase
Additional risk factors include pre-existing gastroparesis, diabetes-related autonomic neuropathy, Parkinson disease, connective tissue disorders affecting gastrointestinal motility, and concurrent use of medications known to slow gastric emptying
Therefore, it proves to be a valuable compound in cardiometabolic and cardiovascular biology research
However, because its not digested or converted into glucose, it has zero net carbs